AI Analysis
AI-generated analysis. Always verify with the original filing.
Persistent operating losses widened to -$17.7M amid R&D investments and impairments, as LockeT sales growth from long-term hospital contracts and sales team expansion provided limited offset while free cash flow burn of -$8.3M signals acute liquidity pressure.
Key Takeaways
1Net income was -$17.7M, reflecting ongoing operating losses deepened by R&D and non-cash impairment charges.
2Net cash provided by operating activities was -$8.3M, driven by negative cash generation from core operations.
3Capital expenditures were $17K, representing minimal investment in fixed assets amid cash constraints.
4Free cash flow was -$8.3M, calculated as operating cash flow less capital expenditures, highlighting sustained cash burn.
5LockeT sales increased due to long-term hospital contracts boosting initial and repeat orders as devices are consumed in procedures.